AIMS: To assess risk of lactic acidosis among metformin users compared with other glucose-lowering agent users, according to renal function. METHODS: Using routine registries and databases, we conducted a cohort study. Of 43 580 metformin and 37 788 other glucose-lowering agent users in northern Denmark and 102 688 metformin and 28 788 other glucose-lowering agent users in the UK during 2001-2011, we identified lactic acidosis using diagnostic codes. We calculated the incidence rates of lactic acidosis in metformin and other glucose-lowering agent users overall and according to baseline estimated GFR (eGFR) levels. RESULTS: In Denmark, the incidence rates of lactic acidosis were 11.6 (95% CI 7.0-18.1) and 1.8 (95% CI 0.4-5.4) per 100 000 person-years of metformin use and of other glucose-lowering agent use, respectively. In the UK, the corresponding lactic acidosis incidence rates were 6.8 (95% CI 4.6-9.6) and 1.0 (95% CI 0.01-5.7) per 100 000 person-years of metformin use and of other glucose-lowering agent use. The incidence rates increased with decreasing baseline eGFR in both countries. Of the metformin-exposed people with lactic acidosis, 37% in Denmark and 34% in the UK experienced a decline in renal function in the year before the diagnosis. CONCLUSIONS: Risk of lactic acidosis was higher in metformin users than in other glucose-lowering agent users, and increased with decreasing eGFR, although this could be attributable to surveillance bias; however, diagnosed lactic acidosis was rare and can occur regardless of renal function.
AIMS: To assess risk of lactic acidosis among metformin users compared with other glucose-lowering agent users, according to renal function. METHODS: Using routine registries and databases, we conducted a cohort study. Of 43 580 metformin and 37 788 other glucose-lowering agent users in northern Denmark and 102 688 metformin and 28 788 other glucose-lowering agent users in the UK during 2001-2011, we identified lactic acidosis using diagnostic codes. We calculated the incidence rates of lactic acidosis in metformin and other glucose-lowering agent users overall and according to baseline estimated GFR (eGFR) levels. RESULTS: In Denmark, the incidence rates of lactic acidosis were 11.6 (95% CI 7.0-18.1) and 1.8 (95% CI 0.4-5.4) per 100 000 person-years of metformin use and of other glucose-lowering agent use, respectively. In the UK, the corresponding lactic acidosis incidence rates were 6.8 (95% CI 4.6-9.6) and 1.0 (95% CI 0.01-5.7) per 100 000 person-years of metformin use and of other glucose-lowering agent use. The incidence rates increased with decreasing baseline eGFR in both countries. Of the metformin-exposed people with lactic acidosis, 37% in Denmark and 34% in the UK experienced a decline in renal function in the year before the diagnosis. CONCLUSIONS: Risk of lactic acidosis was higher in metformin users than in other glucose-lowering agent users, and increased with decreasing eGFR, although this could be attributable to surveillance bias; however, diagnosed lactic acidosis was rare and can occur regardless of renal function.
Authors: Lisa Schlender; Yolanda V Martinez; Charles Adeniji; David Reeves; Barbara Faller; Christina Sommerauer; Thekraiat Al Qur'an; Adrine Woodham; Ilkka Kunnamo; Andreas Sönnichsen; Anna Renom-Guiteras Journal: BMC Geriatr Date: 2017-10-16 Impact factor: 3.921
Authors: Hans-Georg Eichler; Brigitte Bloechl-Daum; Karl Broich; Paul Alexander Kyrle; Jillian Oderkirk; Guido Rasi; Rui Santos Ivo; Ad Schuurman; Thomas Senderovitz; Luke Slawomirski; Martin Wenzl; Valerie Paris Journal: Clin Pharmacol Ther Date: 2018-10-14 Impact factor: 6.875
Authors: Rene A Posma; Trine Frøslev; Bente Jespersen; Iwan C C van der Horst; Daan J Touw; Reimar W Thomsen; Maarten W Nijsten; Christian F Christiansen Journal: Ann Intensive Care Date: 2020-03-26 Impact factor: 6.925
Authors: Pierre Theurey; Guillaume Vial; Eric Fontaine; Pierre-Axel Monternier; Pascale Fouqueray; Sébastien Bolze; David E Moller; Sophie Hallakou-Bozec Journal: Physiol Rep Date: 2022-03